Effect of unfractionated heparin and long-term treatment with low-molecular-weight heparin, bemiparin, on potassium levels

Thromb Haemost 2005; 94(05): 1109-1110
DOI: 10.1055/s-0037-1616815

Letters to the Editor

Schattauer GmbH

Eduardo Rocha

¹University Clinic of Navarra, Pamplona, Spain

,

Antonio Gómez-Outes

²Laboratorios Farmacéuticos Rovi, Madrid, Spain,

,

Javier Martínez Martínez

²Laboratorios Farmacéuticos Rovi, Madrid, Spain,

,

Vijay Vir Kakkar

³Thrombosis Research Institute, London, UK

References
1 Oster JR, Singer I, Fishman LM. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med 1995; 98: 575-86.
2 Koren-Michowitz M, Avni B, Michowitz Y. et al. Early onset of hyperkalemia in patients treated with low molecular weight heparin: a prospective study. Pharmacoepidemiol Drug Saf 2004; 13: 299-302.
3 Gheno G, Cinetto L, Savarino C. et al. Variations of serum potassium level and risk of hyperkalemia in inpatients receiving low-molecular-weight heparin. Eur J Clin Pharmacol 2003; 59: 373-7.
4 Canova CR, Fischler MP, Reinhart WH. Effect of low molecular weight heparin on serum potassium. Lancet 1997; 349: 1447-8.
5 Monreal M, Lafoz E, Salvador R. et al. Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalemia. Eur J Clin Pharmacol 1989; 37: 415-8.
6 Marcelli JM, Lalau JD, Abourachid H. et al. Unlike heparin, low-molecular weight heparin does not suppress aldosterone production. Horm Metab Res 1989; 21: 402.
7 Kakkar VV, Gebska M, Kadziola Z. et al. Low-molecular- weight heparin in the acute and long-term treatment of deep-vein trombosis. Thromb Haemost 2003; 89: 574-80.